Moderna, COVID-19
Investor's Business Daily on MSN4d
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D DayModerna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
Moderna shares have dropped by over -41.67% since I last covered them over the summer. See why I continue to rate MRNA stock ...
Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.
Moderna 's (NASDAQ: MRNA) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a handful of its pipeline programs and terminate a few others. Now, management is ...
Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...
The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...
Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...
Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of ...
Shares of Moderna Inc. MRNA slipped 2.63% to $68.02 Thursday, on what proved to be an all-around favorable trading session ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback